



Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders

Paula A. Garay and A. Kimberley McAllister*

Laboratory of Dr. A.K. McAllister, Department of Neurobiology, Physiology, and Behavior, Center for Neuroscience, University of California, Davis, CA, USA

Edited by:

Susana Cohen-Cory, University of California, USA

Reviewed by:

Lawrence Fargeaud, Salk Institute for Biological Studies, USA

David Stellwagen, McGill University, Canada

*Correspondence:

A. Kimberley McAllister, Center for Neuroscience, UC Davis, 1544 Newton Court, Davis, CA 95618, USA.
e-mail: kmcallister@ucdavis.edu

Although the brain has classically been considered “immune-privileged,” current research suggests an extensive communication between the immune and nervous systems in both health and disease. Recent studies demonstrate that immune molecules are present at the right place and time to modulate the development and function of the healthy and diseased central nervous system (CNS). Indeed, immune molecules play integral roles in the CNS throughout neural development, including affecting neurogenesis, neuronal migration, axon guidance, synapse formation, activity-dependent refinement of circuits, and synaptic plasticity. Moreover, the roles of individual immune molecules in the nervous system may change over development. This review focuses on the effects of immune molecules on neuronal connections in the mammalian central nervous system – specifically the roles for MHC I and its receptors, complement, and cytokines on the function, refinement, and plasticity of geniculate, cortical and hippocampal synapses, and their relationship to neurodevelopmental disorders. **These functions for immune molecules during neural development suggest that they could also mediate pathological responses to chronic elevations of cytokines in neurodevelopmental disorders, including autism spectrum disorders (ASD) and schizophrenia.**

Keywords: cytokine, major histocompatibility complex, complement, synapse, refinement, autism, schizophrenia, plasticity

INTRODUCTION

Although the brain has classically been considered “immune-privileged”, current research suggests that there is **extensive communication between the nervous and the immune systems in both health and disease** (Carson et al., 2006; McAllister and van de Water, 2009). The primary goal of this review is to discuss recent evidence that a large number of “immune” proteins are expressed in the central nervous system (CNS) where they play critical modulatory roles in activity-dependent refinement of connections, synaptic transmission, synaptic plasticity, and homeostasis during brain development. These roles for **immune molecules during neural development suggest that they could also mediate pathological responses to chronic elevations of cytokines in neurodevelopmental disorders, including autism spectrum disorders (ASD) and schizophrenia.**

Ever since the 1900s when bacteriologists Ehrlich, Goldman, and Lewandowsky injected dye into animals and noted that the dye stained all of the organs except for the brain, the concept that the brain is compartmentalized from the rest of the body by the “blood–brain barrier” (BBB) has persisted. Until recently, immune cells were thought to infiltrate the CNS only in rare times of disease or trauma (Maehlen et al., 1989; Amantea et al., 2009). Under these circumstances, glial cells in the brain produce cytokines that cross the BBB and signal recruitment of blood-derived monocytes which migrate back through the compromised BBB into the CNS and aid microglia in causing neural inflammation, degeneration, and cell death (Janeway et al., 2005; Bauer et al., 2007). The effects of immune cell infiltration into the CNS has historically been documented as mostly detrimental, especially in the context of

autoimmune disorders such as paraneoplastic syndrome, multiple sclerosis (MS), and systemic lupus erythematosus (Bhat and Steinman, 2009).

Despite the dogma that peripheral immune responses could not affect CNS function under normal circumstances, substantial evidence over the past 10 years suggests that immune–CNS cross-talk may be the norm rather than the exception. An intriguing example supporting this new idea comes from studies of immune-deficient (severe combined immunodeficient, SCID) mice. These mice, which lack peripheral T-cells, show impairments in the acquisition of cognitive tasks. Repopulating their T cells via bone marrow transfer significantly restores their adaptive immunity and improves learning. Similarly, **acute depletion of adaptive immunity in normal adult mice impairs their learning behavior** (Brynskikh et al., 2008). **Thus, peripheral immune cells can alter cognition in the absence of CNS immune cell infiltration, suggesting that neural–immune cross-talk may involve more than the simple “breaching” of the BBB.**

Moreover, breaching of the BBB may not always be harmful. In traumatic and ischemic injury, MS, infection, and neurodegenerative diseases, activation of an immune response in the CNS may instead contribute to the maintenance, functional integrity, and repair of tissue following an insult (Graber and Dhib-Jalbut, 2009). Furthermore, new therapies for neurodegenerative disorders, including administration of the cytokine interferon-beta (IFN- β) and intravenous immunoglobulin, enhance the protective and regenerative aspects of the immune system in the CNS (Sozzani et al., 2010). A better understanding of both the neuro-protective and destructive roles of the immune response within

the CNS is thus essential for continuing to improve treatments. It is increasingly clear that immune molecules should not be blocked entirely from interaction with the brain, but rather that the interplay between the nervous and immune systems retain balance in order to promote health.

Numerous recent studies (many of which will be centrally addressed in this review) have brought attention to important roles for immune molecules in the nervous system. In the absence of disease, many types of immune molecules are normally expressed in the healthy brain and are essential for brain development (Boulanger, 2009; Carpentier and Palmer, 2009; Deverman and Patterson, 2009). Multiple members of the large family of cytokines are normally produced in the healthy brain where they play critical roles in almost every aspect of neural development, including neurogenesis, migration, differentiation, synapse formation, plasticity, and responses to injury (Boulanger, 2009; Carpentier and Palmer, 2009; Deverman and Patterson, 2009). In addition, other immune molecules from both the innate and adaptive immune systems, including major histocompatibility complex (MHC) I molecules, putative MHCI receptors, and components of the complement cascade have recently been found in the healthy brain during development. These immune molecules play critical roles in synapse refinement and plasticity in the cortex, hippocampus and cerebellum, in information processing in the olfactory system, and in potentially mediating the effects of cytokine infiltration during disease (Boulanger, 2009; Shatz, 2009).

Despite these recent advances, most of the details of when, where, and how immune molecules function in the CNS remain unknown. Moreover, it is unclear if these molecules behave similarly in the CNS as they do in the immune system. Do these molecules have completely novel functions in the CNS or can we deduce their mechanism from their role in the immune system? In order to understand this burgeoning concept of “immune” proteins as key players in brain development and function, it is necessary first to have a basic understanding of their already extensively studied roles in the immune response. For this purpose we will begin this review with an overview of the basic concepts of the immune response, focusing on the immunological roles of a limited number of molecules, including MHCI, cytokines, and complement, whose novel roles in the nervous system will be discussed in later sections. This introduction to the immune system will be followed by sections detailing the localization of immune molecules in the CNS, as well as their roles in refinement of connections, synaptic transmission, plasticity, and homeostatic synaptic scaling. The intent of this review is to highlight the importance of this exciting new research area, underscoring the importance of immune molecules in development and function of connections during brain development and disease.

THE IMMUNE RESPONSE

The immune system, like the nervous system, is highly complex and comprised of specialized components that are fundamental to the existence of an individual. Humans are constantly bombarded with infectious organisms and invading pathogens. Fortunately, we have evolved a highly ordered defense – the immune system. Many details of how the immune response works have been elucidated, but an extensive overview of the immune system is not the purpose of this

review. Instead, we seek here only to draw a basic outline of what is known about specific molecules of interest to neuroscientists and the roles of these molecules in immunity.

Vertebrate immunity is composed of two complementary branches: an innate and an adaptive system (Figure 1; Janeway et al., 2005). Innate immunity produces a rapid response to evolutionarily conserved pathogens and serves as the first line of defense in the immune system. Cells with important roles in the innate immune system include macrophages, dendritic cells and natural killer (NK) cells. If an antigen gets past the innate immune system, it is attacked and destroyed by components of the adaptive immune response composed of highly specialized lymphoid cells, called B and T-lymphocytes, and antigen-specific antibodies that help eliminate pathogens (Janeway et al., 2005). The adaptive response is defined by its ability to recognize and remember specific pathogens and thus mount stronger and more rapid responses upon subsequent exposures to the same pathogen. The adaptive response is dependent upon the innate response. Helping to bridge this connection are certain proteins common to both pathways including those of the complement system as well as signaling molecules called cytokines that play key roles in the initial innate immune response and the subsequent adaptive response (Rothman et al., 1990; Janeway et al., 2005).

CYTOKINES

The ability to convey information is fundamental to an effective immune system, making signaling molecules of paramount importance. Cytokines are one of the largest and most diverse families of signaling molecules in the body. Under healthy conditions, most cytokines circulate at very low concentrations but can increase up to 1,000-fold during trauma or infection (Janeway et al., 2005). Released early in the immune response, they cause a myriad of outcomes including increased MHCI expression and secretion of additional cytokines which augment inflammatory responses (Linda et al., 1998). Cytokines bind to specific membrane receptors, which then signal via second messengers eventually resulting in alterations in gene transcription. There are more than 50 known cytokines, often classified into pro- and anti-inflammatory families. The major pro-inflammatory cytokines responsible for early responses are IL1- α , IL1- β , IL-6, and TNF- α . Other pro-inflammatory mediators include LIF, IFN- γ , OSM, CNTF, TGF- β , GM-CSF, IL11, IL12, IL17, IL18, and a variety of chemokines such as IL-8, CCL2 (MCP-1), CCL5 (RANTES), and CX3CL1 (Fractalkine) that chemoattract inflammatory cells. Anti-inflammatory cytokines limit the potentially detrimental effects of sustained or excess inflammatory reactions. The major anti-inflammatory cytokines include the interleukin (IL)-1 receptor antagonist (IL-1ra), IL-4, IL-6, IL-10, IL-11, IL-13, and TGF- β . With the possible exception of IL-1ra, all of these anti-inflammatory cytokines have at least some pro-inflammatory properties (Janeway et al., 2005). A highly dynamic balance exists between pro- and anti-inflammatory cytokines and this signaling can result in diverse outcomes, such as increased or decreased expression of membrane proteins, proliferation, and/or secretion of effector molecules. In fact, it is often difficult to make generalizations about the roles of individual cytokines due to their frequently redundant and pleiotropic effects. To add to this complexity, combinations of cytokines can act either synergistically or




FIGURE 1 | Innate and adaptive immunity. A simplified schematic of the two branches of the immune response. Following injury or infection, pathogens (bacteria, virus or foreign protein) infiltrate tissue. The innate response provides immediate defense against infection (1–5): 1. Neutrophils engulf the pathogen and destroy it by releasing antimicrobial toxins. 2. Macrophages can directly phagocytose pathogens, leading to production of cytokines and recruitment of more cells from the blood. 3. Infected cells displaying low levels of MHC1 on their surface are directly detected by natural killer (NK) cells, which release lytic enzymes causing the infected cell to die via apoptosis. 4. Bacteria can also be recognized by the complement system, resulting in their lysis. 5. Macrophages and dendritic cells can become antigen presenting cells (APCs) by taking up peripheral antigens and migrating to lymph nodes to present antigen on their surface to naïve B- and T- cells. The adaptive response confers the ability to

recognize and remember specific pathogens to generate immunity (6–11): 6. APC interaction with B- and T- cells in the lymph nodes leads to B- and T-cell activation and migration to the periphery where they mediate adaptive immunity. 7. Once activated, the T-cell undergoes a process of clonal expansion in which it divides rapidly to produce multiple identical effector cells. Activated T-cells then travel to the periphery in search of infected cells displaying cognate antigen/MHC1 complex. 8. Peripheral APCs induce helper T cells to release cytokines and recruit cytotoxic T cells (CTL). 9. Activated antigen-specific B cells receiving signals from helper T-cells differentiate into plasma cells and secrete antibodies. 10. Antibodies bind to target antigens forming immune complexes which can then activate complement or be taken up by macrophages through Fc receptors 11. Formation of cytotoxic T-cell synapses causes lysis of the infected cell.

antagonistically depending on the state of the target cells and the combinations, doses, and temporal sequence of cytokine secretion (Janeway et al., 2005).

In this review, we will focus mostly on three cytokines that have been extensively studied in the nervous system – tumor necrosis factor (TNF), interleukin (IL)-1, and IL-6. Deregulated

overproduction of these three pro-inflammatory cytokines as well as the resultant disequilibrium between pro-inflammatory and anti-inflammatory functions, have been shown to underlie the pathophysiology of many diseases such as autoimmune diseases, therefore these cytokines are attractive candidates for central signaling roles (Hawkes et al., 1999; Cunningham et al., 1996). All three of these cytokines are involved in the acute immune response and initial inflammation. They are produced by many cell types including macrophages, monocytes, fibroblasts, dendritic cells, T cells, B cells, monocytes, fibroblasts, and endothelial cells. Among one of the first cytokines discovered, IL-1 (α and β) is most potent at activating fever. IL-6 was originally identified as a T-cell-derived factor that induces activated B cells to differentiate into antibody-producing cells (Figure 1). TNF α is well known for its ability to induce inflammation, inhibit tumorigenesis and viral replication, and to induce apoptotic cell death. Although these three cytokines are associated with the acute response in innate immunity, they also act to regulate molecules associated with adaptive immunity such as MHC I.

MHCI

Because activation of adaptive immunity can be highly destructive, it is essential that it is activated only in response to foreign proteins and not to self proteins (Janeway et al., 2005). The adaptive immune response is triggered by recognition of non-self antigens, which are displayed on antigen presenting cells (APCs) through MHC. MHC I proteins are cell-surface ligands that bind to T cell receptors (TCR) and other immunoreceptors and act to regulate the activation state of immune cells. One of the defining features of MHC molecules and their receptors is their complexity. They are both polygenic-containing multiple genes and polymorphic-containing multiple variants of each gene. The MHC genes are the most polymorphic genes known (Janeway et al., 2005). The specific genes and variants that an individual expresses comprise its MHC I haplotype. The human MHC is encoded on chromosome 6 and contains 140 genes. In humans, there are three classical MHC I genes, the HLA class I antigens A, B, and C; the other MHC I genes are classified as non-classical. The rat MHC is encoded on chromosome 20 and contains a classical class I MHC-encoding region, RT1A, and other adjacent encoding regions including a non-classical class I MHC-encoding region, RT1-C/E/M. The RT1A region of the RT1 complex encodes between 1 and 3 classical class I molecules, depending on the rat strain. The mouse MHC I region is located on chromosome 17 and encodes the three H-2 genes – H2-K, H2-D, and H2-L. Each inbred mouse strain expresses a unique combination of MHC I molecules. Each of the classical MHC I molecules includes a β 2-microglobulin (β 2m) light chain, encoded by a single gene. Finally, the non-classical MHC I region in both rats and mice encodes numerous molecules, many of which have not yet been characterized even in the immune system (Abbas et al., 2000).


Classical MHC I molecules are trimeric proteins comprised of a transmembrane heavy chain, the β 2m light chain, and a peptide bound in the groove of the heavy chain. Complete trimers are transported to the cell surface of almost all cells in the body (Machold and Ploegh, 1996). Peptides presented by MHC I heavy chain on the cell surface are derived from proteolysis of intracellular proteins and are monitored by T-cells. The T-cell repertoire

is established during development through the creation of millions of T-cells, each harboring a unique TCR. When a TCR binds to an MHC molecule presenting a non-self peptide, an immunological synapse is formed (Figure 2A). The immune synapse consists of the TCR ($\alpha\beta$ subunits) bound by a cluster of differentiation protein 3 complex (CD3) and ζ -chain (CD3 ζ) proteins. In mammals, the CD3 complex contains a CD3 γ chain, a CD3 δ chain, and two CD3 ϵ chains. The CD3 γ , CD3 δ , and CD3 ϵ chains are highly related cell-surface proteins of the immunoglobulin superfamily containing a single extracellular immunoglobulin domain. Formation of the complete T-cell immune synapse initiates an immune response, leading to eventual lysis of cells displaying foreign peptide (Cantrell, 1996; Abbas et al., 2000).

In addition to binding T-cell receptors, MHC I molecules also bind to inhibitory receptors (IRs) on natural killer (NK) cells, which are part of the innate immune system (Krzewski and Strominger, 2008; Long, 2008). There are three major families of MHC I receptors found on NK cells including killer cell-immunoglobulin receptor (KIR), CD94/NKG2 and leukocyte immunoglobulin-like receptor (LILR) in humans and LY49, murine NKG2 and the paired immunoglobulin-like receptor (PIR) receptors in rodents. Each family has multiple members that can either inhibit or activate apoptosis of a target cell. The balance between activating and inhibitory receptor (IR) signaling on the NK–target cell interface determines the outcome of the interaction. A lack of MHC I on the target cell, caused by viral infection or tumorigenesis, favors formation of the activating immune synapse (Figure 2B). Conversely, the presence of MHC I on the target cell results in binding of MHC I to NK-IRs, which initiate a classical NK-IR signaling pathway that prevents the formation of immune synapses required for NK activation and apoptosis of the target cell (Krzewski and Strominger, 2008; Long, 2008).

THE COMPLEMENT SYSTEM

The complement system is a critical component of both innate and adaptive immunity. Although the complement system is most commonly classified under innate immunity, this process is also induced by antibodies, constituents of adaptive immunity, to more rapidly mark pathogens for destruction (Janeway et al., 2005). Activation of complement initiates a complex biochemical activation cascade of over 25 proteins and protein fragments that opsonize pathogens and induce inflammatory responses. It consists of three distinct pathways – the classical, the mannose binding lectin (MBL), and the alternative pathways, that all depend on different molecules for their initiation but converge on the C3-convertase and result in the same cascade of complement activation. The classical pathway is triggered by activation of the C1 complex (C1q, two C1r, and two C1s molecules thus forming C1q r^2s^2), which occurs when C1q binds to antibody: antigen complexes or when C1q binds directly to the surface of a pathogen. Binding leads to conformational changes in the C1q molecule, in turn leading to the activation of complement proteases that cleave specific proteins to release cytokines and initiate a cascade of further cleavages, resulting in amplification of the response and activation of the cell-killing membrane attack complex. C3-convertase cleaves and activates component C3, creating C3a and C3b and causes a cascade of further cleavage and activation events. Activation of the complement cascade leads to lysis of the target cell.



IMMUNE MOLECULES ARE PRESENT IN HEALTHY NEURONS AND GLIA

It has been appreciated for years that stress, trauma, infection, and seizures can increase neural-immune cross-talk. These insults all

have dramatic effects on increasing cytokine expression in both neurons and glia. In turn, at least some cytokines like IFN γ upregulate MHC1 expression in central and peripheral neurons *in vitro* and *in vivo* (Fujimaki et al., 1996; Zhou, 2009). However, in the past 10 years, discoveries that immune molecules are expressed

in the healthy CNS and are essential for brain development have disproven the once-dominant paradigm of CNS immune privilege (Boulanger, 2009; Carpentier and Palmer, 2009; Deverman and Patterson, 2009). The presence of immune molecules in the CNS was overlooked until recently in large part because the expression patterns of many immune proteins in the CNS change over development and the levels of expression under normal healthy conditions tend to be quite low. This makes detecting mRNA and protein challenging and may have added to the misconception that immune molecules are only expressed in the CNS during periods of infection or trauma.

The nervous and immune systems share many proteins (Tian et al., 1999; Khan et al., 2001; Pacheco et al., 2004; Suzuki et al., 2008), including cytokines, MHCI, and proteins of the complement system to name a few. Both systems also employ tightly controlled communication through specialized, sophisticated cell–cell junctions called synapses (Figure 2; Yamada and Nelson, 2007). Confining the molecules released – neurotransmitters in the CNS and lytic enzymes and cytokines in the immune system – to synapses ensures that they will act specifically and locally on target cells, with minimal effects on neighboring cells. Immunological synapses can form between a T-cell and an APC (Figure 2A) and between an NK cell and a target cell (Figure 2B; Yamada and Nelson, 2007). Just as the immune synapse transfers information and is necessary for immune activation, the CNS synapse (Figure 2C) transfers information and is necessary for cognition. Although the synaptic localization of most immune molecules in neurons remains understudied, especially *in vivo*, several immune molecules and/or receptors, including some cytokines and their receptors (Vikman et al., 1998; Kubota et al., 2009), MHCI molecules (Huh et al., 2000) and components of the complement system (Stevens et al., 2007) have functions associated with synaptic changes in the healthy CNS (see Roles of immune molecules in the healthy CNS). It is tempting to speculate that immune molecules will play a similar role at the CNS synapse as at the immune synapse, but much more needs to be known about location and function of immune molecules in the CNS to draw direct parallels.

CYTOKINES IN THE CNS

For years it has been well-established that many cytokines, chemokines, and their receptors are constitutively expressed in the brain throughout development and in the adult. Although many cytokines and their receptors remain unstudied, the major cytokines IL1- α , IL1- β , IL-4, IL-6, IL-10, IL-11, IL-13, IL-18, TNF- α , IL1-ra, TGF- β , and CCL2 are all expressed in the healthy CNS (Bauer et al., 2007). Many of these cytokines and their receptors have differential expression patterns across the CNS that vary over development (Takao et al., 1992; Gadiant and Otten, 1994; Pousset, 1994). For example, mRNAs for IL-6 and its receptor (IL-6R) are developmentally regulated in a tissue-specific manner in the rat brain (Gadiant and Otten, 1994). The adult hippocampus has the highest detectable levels of both transcripts, while IL-6 mRNA levels are highest during early brain development in most other brain regions. Levels of IL-6 mRNA can be dramatically upregulated with age; they increase up to 8-fold in the striatum during development (Gadiant and Otten, 1994). In the majority of studies, the expression profiles of cytokines and their recep-

tors have been examined using *in situ* hybridization and RT-PCR in rodent brains (Rothwell and Hopkins, 1995; Rothwell et al., 1996; Meng et al., 1999; Ishii and Mombaerts, 2008). Confirming cytokine expression at the protein level in the CNS has been challenging and remains mostly incomplete given the purported lack of specificity of many commercially available antibodies necessary for western blot and immunocytochemistry experiments. Despite this caveat, it is clear that cytokines are produced by, and can act on, almost all CNS cells including neurons, astrocytes, and resident microglia (Hopkins and Rothwell, 1995; Mehler and Kessler, 1995; Kaufmann et al., 2001; Kielian et al., 2002; Geppert, 2003; Harkness et al., 2003; Koyama et al., 2007). Interestingly, IFN- γ and is found at neuronal synapses (Vikman et al., 1998) suggesting that it may act at the level of the synapse to influence brain function. In order to generate well-informed hypotheses for the function of cytokines in the healthy CNS, the field of neuroimmunology must generate specific antibodies to cytokines and their receptors and use them to determine their distribution during development and plasticity. In addition, an understanding of the signaling mechanisms underlying cytokine function in neurons is needed to provide essential insights into the roles of cytokines that regulate normal and abnormal brain functions.

MHCI IN THE CNS

Perhaps the biggest surprise in this field has been the discovery that many of the proteins central to the innate and adaptive immune responses are found on neurons and glia in the healthy brain (Ishii and Mombaerts, 2008). One of the first and most influential papers to demonstrate this constitutive expression was published 12 years ago from the Shatz laboratory (Corriveau et al., 1998). Using an unbiased PCR-based differential display screen for activity-regulated genes in the developing feline visual system, the Shatz lab discovered a substantial decrease in neuronal MHCI mRNA following activity blockade. Examination of the expression of several MHCI forms using *in situ* hybridization showed that MHCI molecules are expressed in unique, spatially and temporally restricted patterns in healthy, unmanipulated brains (Corriveau et al., 1998). Subsequently, MHCI mRNA and/or protein has been detected in several neuronal populations, including dorsal root ganglia neurons and brainstem motoneurons (Lidman et al., 1999; Loconto et al., 2003; Edstrom et al., 2004; Harnesk et al., 2009) as well as developing and adult hippocampal pyramidal (Neumann et al., 1997; Corriveau et al., 1998; Goddard et al., 2007; Ribic et al., 2010) and cerebellar (Corriveau et al., 1998; McConnell et al., 2009) neurons. MHCI protein is also enriched in neuronal synaptic membranes (Huh et al., 2000).

The search for the receptor through which MHCI functions in neurons has been much more challenging than initially expected. In the immune system, peptide-presenting MHCI molecules are usually thought to bind to T-cell receptors (TCRs) to mediate the adaptive immune response. However, there is no evidence for TCR α or TCR protein in neurons (Syken and Shatz, 2003; Boulanger and Shatz, 2004). Yet, many other immunoreceptors and associated effector molecules for MHCI such as PIRB (Syken et al., 2006; Atwal et al., 2008), Ly49 receptors (Zohar et al., 2008), KIR (Bryceson et al., 2005), and CD3 ζ (Corriveau et al., 1998; Xu et al., 2010) are all found in the CNS where they display distinct

gene expression and/or protein patterns and most are expressed in highly plastic regions. PirB is found throughout the CNS, and is present in the visual system during the period of activity-dependent plasticity (Syken et al., 2006). PirB protein is localized to axonal growth cones and dendrites, where it is often very close to, but rarely overlaps with, the presynaptic proteins synaptophysin or synapsin, suggesting that PirB is localized near synapses (Syken et al., 2006). Ly49 mRNA is also amply expressed in the cerebral cortex, hippocampus, hypothalamus, and cerebellum in adult mouse brain (Zohar et al., 2008). Ly49 protein in neurites colocalizes with synapsin and alternates with the postsynaptic marker Shank (Zohar et al., 2008). KIR genes are selectively expressed in olfactory bulbs, rostral migratory stream, and dentate gyrus of hippocampus, subregions of the mouse brain where synaptic plasticity and neurogenesis occur (Bryceson et al., 2005). Finally, CD3 ζ is also found throughout the developing and adult CNS and in the retina, where it is preferentially expressed by retinal ganglion cells (RGC) and colocalizes with PSD95 and CtBP2, a presynaptic ribbon protein in the IPL during the period of synaptic formation (Xu et al., 2010).

Mechanistically, MHCI may act through one or all of these receptors in an analogous fashion to its signaling in the immune system. However, the documented expression patterns of MHCI immunoreceptors do not adequately account for the documented functions (see below) and diversity of localization of specific MHCI forms. Thus, MHCI may bind multiple receptors or as yet unidentified neuronal receptors. In the future, the subcellular distribution of MHCI in neurons, at synapses, and in all glial cell types must be determined in order to propose testable models for MHCI function. Proteomic and biochemical identification of all possible MHCI receptors and downstream signaling molecules, as well as the development of more specific antibodies to localize all of the MHCI and MHCI receptor subtypes, are essential to clarify these fundamental issues.

COMPLEMENT

In addition to cytokines and MHCI, essential components of the complement cascade, including C1q and C3, are also expressed in the CNS. They are expressed in a punctate pattern in the developing but not the adult brain, peaking during periods of synapse formation and activity-dependent refinement (Perry and O'Connor, 2008). In the retina, C1q protein is detected in immunostained cryosections in the synaptic inner plexiform layer (IPL) of postnatal mouse retinas and in developing RGCs. It colocalizes with synaptic proteins, postsynaptic density-95 (PSD-95) and synaptophysin puncta – mostly with one or the other of these proteins, but not often with both, **at non-synaptic sites in the early postnatal retina**. RGCs upregulate complement proteins in response to secreted molecules from astrocytes (Stevens et al., 2007). Moreover, C1q is often colocalized with MHCI at synapses between hippocampal neurons (Datwani et al., 2009), suggesting that **these immune molecules may interact to alter synaptic function**.

ROLES OF IMMUNE MOLECULES IN THE HEALTHY CNS

Immune molecules are present at the right place and time to modulate the development and function of the healthy and diseased CNS. Indeed, recent research suggests that immune molecules

play integral roles in the CNS throughout neural development, including affecting neurogenesis, neuronal migration, axon guidance, synapse formation, activity-dependent refinement of circuits, and synaptic plasticity (Zhao and Schwartz, 1998; Deverman and Patterson, 2009). Complicating this already complex field is the observation that the **functions of individual immune molecules in the nervous system may change over development**. For example, during sequential stages of development, TGF β regulates neural induction, cell lineage commitment, neuronal differentiation, axon growth and guidance (Pousset, 1994; Charron and Tessier-Lavigne, 2007), and neuromuscular synapse formation and function (Sanyal et al., 2004; Feng and Ko, 2008; Heupel et al., 2008). Because we cannot adequately cover all of the roles for immune molecules in CNS development in a single review, we focus here on the effects of immune molecules on neuronal connections – specifically on the function, refinement, and plasticity of primarily geniculate, cortical and hippocampal synapses, and their relationship to neurodevelopmental disorders.

REFINEMENT OF CONNECTIVITY

In order to create cohesive synaptic networks, appropriate connections must be formed and superfluous ones selectively eliminated. Most studies of the effects of immune molecules on refinement of connections in the CNS during development have used one of the most classical models for activity-dependent refinement of connections – visual system plasticity (Shatz, 2009). Visual information is carried from the retina through RGC axons into the lateral geniculate nucleus (LGN) of the thalamus and from there up to primary visual cortex. In binocular adult animals, axons carrying information from each eye are segregated into eye-specific layers in the LGN and into eye-specific regions, called ocular dominance (OD) columns, in layer 4 of visual cortex. Initially, inputs from each eye are thought to overlap in both the LGN and cortex and then become segregated later only after a period of activity-dependent synaptic refinement (Katz and Shatz, 1996). Studies from many laboratories have demonstrated that segregation of both retinogeniculate and geniculocortical axons is activity-dependent and involves competition between axons from each eye (Katz and Shatz, 1996; Hua and Smith, 2004). During critical periods, neural activity sculpts connections by strengthening and stabilizing subsets of synapses and weakening and eliminating others. If vision is restricted to only one eye during this critical period, the areas innervated by the deprived eye shrink while those innervated by the non-deprived eye expand (Katz and Shatz, 1996).

How neural activity ultimately leads to refinement is not well understood, but immune molecules appear to play an important role in this process. MHCI genes were first identified in the LGN in a screen for genes involved in the activity-dependent refinement of retinogeniculate axons (Corriveau et al., 1998). More recently, components of both the innate and adaptive immune systems – MHCI, its receptors, and complement – have been implicated in this process (Boulanger et al., 2001; Oliveira et al., 2004). The prevailing hypothesis in this field is that immune molecules in neurons engage MHCI receptors, generating common intracellular signals in both neurons and immune cells that ultimately alter synaptic strength, neuronal morphology, and circuit properties downstream of synaptic activity (Boulanger et al., 2001; Syken et al., 2006; Fourgeaud and Boulanger, 2007).

Consistent with this idea, transgenic mice have been used to discover dramatic effects of immune molecules on refinement of connectivity during brain development. In order to determine the role for MHCI during activity-dependent plasticity, retinogeniculate projections were examined in $\beta 2m/TAP1$ double-knockout (DKO) mice, in which MHCI on the surface of their cells is dramatically decreased due to the lack of $\beta 2m$, the MHCI light chain required for transport of MHCI to the membrane, and the transporter associated with antigen processing 1 (TAP1), which packages proteasomal peptides required for most MHCI receptor-mediated signaling (Abbas et al., 2000). These $\beta 2m/TAP1$ DKO mice have a significantly larger projection from the ipsilateral eye in the LGN (Corriveau et al., 1998; Huh et al., 2000), interpreted as indicating a lack of pruning of the inappropriate retinogeniculate axons. A similar impairment of refinement of retinogeniculate layers was found in an MHCI KO mouse lacking both H2-K^b and H2-D^b genes (Datwani et al., 2009) and in mice lacking CD3 ζ (Huh et al., 2000). Interestingly, OD plasticity was enhanced in the K^bD^b KO mouse (Datwani et al., 2009), further supporting the conclusion that MHCI might be critical for mediating the effects of activity in modifying neural connections (Huh et al., 2000). Because the PirB KO mouse phenocopies the enhanced OD plasticity in the K^bD^b KO, PirB is likely the MHCI receptor in cortex (Syken et al., 2006; Datwani et al., 2009). However, retinogeniculate remodeling was unaltered in the PirB KO (Syken et al., 2006), implying that there are likely additional means by which MHCI molecules exert their effects in the developing LGN.

Although the hypothesis that MHCI acts at CNS synapses to mediate activity-dependent synaptic weakening and elimination of inappropriate connections (Shatz, 2009) is consistent with effects of MHCI on synaptic plasticity (see below), a recent report has suggested an alternate hypothesis – that MHCI contributes to retinogeniculate refinement indirectly by altering the structure and function of RGCs (Xu et al., 2010). CD3 ζ is expressed in RGCs and CD3 ζ -deficient mice exhibit reduced RGC dendritic motility, an increase in RGC dendritic density, and a selective defect of glutamate-receptor-mediated synaptic activity in the retina (Xu et al., 2010). In contrast with previously reported hypotheses that MHCI directly regulates refinement, this change in glutamate-receptor-mediated synaptic activity suggests that MHCI may instead be altering activity patterns and thus indirectly affecting refinement. Furthermore, it is clear that MHCI is not required for all forms of activity-dependent refinement since loss of MHCI molecules does not alter refinement of climbing fiber-Purkinje cell projections (Letellier et al., 2008; McConnell et al., 2009). Thus, the roles for MHCI in refinement of connections during CNS development may be complex and system-specific. There is much to be done to fully understand the effects of these immune molecules in brain development. Elucidating the precise role for MHCI molecules and its receptors in synaptic refinement is a critical issue for this field.

Classical complement proteins also play a role in retinogeniculate refinement. Like those seen in the $\beta 2m/TAP1$ DKO mice, defects in eye-specific segregation occur in mice in which components of the complement cascade are knocked out (C1q and C3 KOs), thus complement may mediate activity-dependent elimination of exuberant connections (Stevens et al., 2007). Using a gene profiling

approach on RGCs, immature astrocytes were found to induce the expression of the C1qA, C1qB, C1q – components of the complement system – on neurons (Stevens et al., 2007). C1q localizes to synapses both in culture and in the postnatal CNS and this expression significantly declines by P30 (Stevens et al., 2007). Although the mechanism by which complement-tagged synapses might be eliminated has not been discovered, it is possible that microglia expressing the C3 receptor may be involved (Gasque et al., 1998). In motor neurons, microglia have been proposed to eliminate synapses via phagocytosis-synaptic stripping (Schiefer et al., 1999) and a similar process may occur in the CNS. Whether complement and MHCI molecules interact to regulate activity-dependent refinement of connections has not yet been addressed. **A major challenge for this field in the future will be to determine whether and how immune molecules interact mechanistically to alter connectivity in the developing CNS.**

The role of cytokines and their receptors in refinement of connections in the developing CNS is much less clear. However, two recent studies suggest that these diffusible factors are key players in this process. First, following monocular lid suture, mice deficient in TNF α show the normal initial decrease in cortical responses from the deprived eye, but do not show the subsequent increase in response to the open eye (Kaneko et al., 2008). Second, chronic exposure of *Xenopus* to TNF α decreases the number of immature synapses containing only NMDARs and no AMPARs on tectal neurons. **Thus, chronic exposure to this pro-inflammatory cytokine may cause premature maturation and stabilization of these synapses** (Lee et al., 2010). Interestingly, TNF α increases the growth of dendrites of tectal neurons and enhances connectivity, similar to what is seen in immature, less well-refined tectal circuits (Lee et al., 2010). **Given the widespread effects of many cytokines on synaptic plasticity (see below), especially long-term potentiation and depression which are believed to underlie activity-dependent refinement of connections** (Hensch et al., 1998), it is likely that many members of the **large family of cytokines will also play important roles in refinement of connections in the developing brain.**

Although exuberant connectivity in the visual system in $\beta 2m/TAP1$ DKO, PirB KO, H2-K^b/H2-D^b DKO, C1q KO, and C3 KO mice has been interpreted to indicate a lack of synapse elimination, it is equally possible that this phenotype is the result of increased axonal growth, synapse formation, and/or synapse stabilization. Clarifying this issue is absolutely critical to understand how these molecules alter activity-dependent refinement of connections. Yet, there is currently no assay available that can distinguish whether a molecule changes synapse density through altering the formation or elimination of synapses. Development of new assays allowing long-term imaging of synaptic connections is critical to address this fundamental issue in the future.

SYNAPTIC TRANSMISSION

In addition to mediating activity-dependent refinement of connections during CNS development, **many immune molecules also regulate synaptic transmission between hippocampal and cortical neurons.** For example, MHCI molecules affect basal transmission at glutamatergic synapses in cultured hippocampal neurons and cortical slices. $\beta 2m/TAP1$ DKO mice exhibit slightly larger presynaptic terminals in cultured hippocampal neurons and a small

(10%) but significant increase in the number of synaptic vesicles at synapses in adult hippocampal slices as determined by electron microscopy (Goddard et al., 2007). Consistent with these changes in synaptic composition, mEPSCs are altered in cultured hippocampal neurons from $\beta 2m/TAP1$ DKO mice compared to controls. mEPSC frequency increases by 40% in hippocampal DKO cultures and by over 100% in acute cortical slices from DKO mice, while mEPSC amplitude is unchanged. Because the authors did not detect a change in synapse density in their DKO hippocampal cultures, they interpreted the increase in mEPSC frequency as due to a change in synaptic vesicle release probability (Goddard et al., 2007). The cause of the 100% increase in mEPSC frequency in cortical slices was not assessed. Finally, H2-K^bD^b DKO mice show enhanced presynaptic glutamate release at climbing fiber (CF)-Purkinje cell (PC) synapses in the cerebellum (McConnell et al., 2009). Measures of postsynaptic function, including mEPSC amplitude, were not altered by manipulation of MHCI levels in either system, suggesting that MHCI molecules selectively regulate synaptic vesicle release.

Several cytokines also alter synaptic transmission, but the nature of their effects is highly dependent on the specific cytokine studied and its dose. For example, recombinant IL-1 β decreases the frequencies but not the amplitudes of spontaneous excitatory postsynaptic currents (sEPSC) and mEPSCs in cultured hippocampal neurons. IL-1 β also increases the NMDA receptor-mediated current and the amplitude of the voltage-dependent Ca²⁺ current (I_{Ca}), in a dose-dependent manner (Yang et al., 2005). Conversely, recombinant TGF $\beta 2$ increases both the frequency and amplitude of mEPSCs in hippocampal neurons (Fukushima et al., 2007). Similarly, recombinant TNF- α increases mEPSC frequency and amplitude and enhances EPSPs (Beattie et al., 2002; Stellwagen et al., 2005; Stellwagen and Malenka, 2006). TNF α works in large part by promoting the surface accumulation of AMPA-type glutamate receptors (AMPA) in hippocampal neurons *in vitro* (Beattie et al., 2002). TNF α appears to work primarily postsynaptically since there is no effect on paired-pulse facilitation, a measure of presynaptic function (Beattie et al., 2002). Similarly, blocking endogenous TNF α using a soluble TNF receptor, sTNFR1, decreases mEPSC frequency and amplitude, surface AMPAR levels, and the AMPA/NMDA ratio in hippocampal slices (Beattie et al., 2002; Stellwagen et al., 2005). While it is unclear if all cytokines are released from glia, the endogenous TNF α that alters synaptic transmission does come primarily from glial sources (Beattie et al., 2002; Stellwagen et al., 2005).

In contrast to their effects on the function of excitatory synapses, the effects of immune molecules on inhibitory synapses remain mostly unknown. MHCI may control GABAergic inputs since it is a target of the transcription factor Npas4, which enhances GABAergic synapse density (Lin et al., 2008). Likewise, several cytokines, including IL-1 β (Zeise et al., 1992) and TNF- α (Stellwagen et al., 2005) regulate inhibitory synaptic transmission. Recombinant IL-1 β inhibits GABAergic currents and GABAergic synaptic transmission in hippocampal neurons (Zeise et al., 1992; Wang et al., 2000). Similarly, recombinant TNF α decreases the strength of GABAergic synapses (Stellwagen et al., 2005), suggesting that TNF α could mediate the balance between excitation and inhibition on hippocampal neurons. Because so little is known about

the effects of immune molecules on inhibition, **future studies are necessary to better understand the potential effects of immune molecules on the ratio of excitatory-to-inhibitory synapses.**

SYNAPTIC PLASTICITY

The cellular mechanisms underlying activity-dependent refinement of connections during CNS development are thought to involve a regulated combination of Hebbian synaptic plasticity –long-term plasticity (LTP) and long-term depression (LTD) – and homeostatic plasticity. Many immune molecules studied to date modulate one or both of these forms of long-term plasticity (Bauer et al., 2007; Boulanger, 2009).

LTP/LTD

Although the mechanisms through which MHCI molecules regulate activity-dependent refinement of circuits are yet unclear, many manipulations of MHCI result in changes to long-term plasticity. Hippocampal LTP is enhanced (Huh et al., 2000; Barco et al., 2005) and LTD is abolished at standard stimulation frequencies in $\beta 2m/TAP1$ DKO mice (Huh et al., 2000). Like MHCI, CD3 ζ is also required for hippocampal LTD and limits LTP (Huh et al., 2000). Finally, another signaling component of MHCI receptors in immune cells – DAP12 – also limits LTP (Roumier et al., 2004, 2008). Together these results support the interpretation that MHCI molecules play an integral role in activity-dependent plasticity specifically by enhancing synapse weakening and possibly elimination.

The role for MHCI in long-term plasticity is dependent upon the circuit analyzed. Two specific MHCI molecules, H2-K^b and H2-D^b increase the threshold for LTD at parallel fiber (PF)-PC synapses in the adult cerebellum. Mice deficient in both these forms of MHCI show improved performance on the rotarod behavioral test, indicative of enhanced cerebellar plasticity (McConnell et al., 2009). Interestingly, rotarod performance at high speed is reduced in CD3 ϵ KO mice (Nakamura et al., 2007) while similar tests on CD3 ζ KO mice and PirB deficient mice show no impairments (McConnell et al., 2009). Future studies are needed to determine if and how MHCI alters long-term plasticity in different areas of the CNS using similar or distinct mechanisms.

Similar to MHCI molecules and its co-receptors, a growing number of cytokines, including TNF- α , IL-1 β (Katsuki et al., 1990; Cunningham et al., 1996; Spulber et al., 2009), IL-2 (Tancredi et al., 1990), IL-6 (Bellinger et al., 1995; Li et al., 1997; Tancredi et al., 2000), IL-8 (Xiong et al., 2003), IL-18 (Curran and O'Connor, 2001; Alboni et al., 2010), TGF β , and interferon- α and - β (D'Arcangelo et al., 1991; Mendoza-Fernandez et al., 2000) all inhibit hippocampal LTP. These cytokine-induced effects are dose-dependent and mediated by distinct receptors (D'Arcangelo et al., 1991). Exogenous TNF α may inhibit LTP (Tancredi et al., 1992) and LTD is abolished in mice lacking the TNF receptor (Albensi and Mattson, 2000). The role of TNF α in LTP and LTD has been questioned, however, by recent results published by two groups showing no impairment in hippocampal and cortical LTP and LTD in TNF α - and TNFR-deficient mice (Stellwagen and Malenka, 2006; Kaneko et al., 2008). IL-6 and IL-2 inhibit LTP and short-term potentiation (STP) in a dose-dependent manner (Li et al., 1997). In addition, IL-1 β , IL-6, and TNF- α regulate synaptic plasticity in models of learning and memory and have been associated with

cognitive decline and dementia (Schmidt et al., 2002; Holmes et al., 2003; Dik et al., 2005). Moreover, IL-1 β blocks induction of LTP in the mossy fiber CA3 pathway of mouse hippocampal slices (Katsuki et al., 1990) and this effect can be mimicked with TNF- α and LPS in slices (Katsuki et al., 1990; Cunningham et al., 1996). IL-18 depresses the amplitude of pharmacologically isolated NMDA receptor-mediated fEPSPs and impairs LTP in hippocampal slices (Curran and O'Connor, 2001). Finally, LTP induction in turn upregulates levels of IL-1 β , TGF β , and IL-6 (Jankowsky et al., 2000; Balschun et al., 2004). Thus, alterations in the levels of cytokines can profoundly change synaptic efficacy, and changes in synaptic function can alter cytokine levels. Because all of the cytokines tested so far limit LTP, it is important in the near future to determine if they act through common or distinct pathways to alter mechanisms of LTP expression.

Synaptic scaling (homeostasis)

In addition to their effects on Hebbian plasticity, immune molecules have also been implicated in the regulation of homeostatic plasticity. **The concept of homeostasis is ubiquitous in biology. In order to maintain balance in any system, a method to insure that it can function independently of fluctuating environments must be in place.** In neural networks, this homeostatic mechanism is known as synaptic scaling or homeostatic plasticity (Turrigiano, 2008). Synaptic scaling occurs in both cultured neurons and in hippocampal slices, although in slice it appears to be heterogeneous, varying in both a target- and afferent-specific manner (Kim and Tsien, 2008). Dynamic, activity-dependent AMPAR trafficking may underlie synaptic scaling and is seen in several experience-driven phenomena – from neuronal circuit formation to alterations of behavior (Kessels and Malinow, 2009). Synaptic homeostasis is thought to prevent positive feedback mechanisms in neural circuits from destabilizing over time and becoming hyper- or hypo-active (Desai et al., 2002; Ibata et al., 2008; Turrigiano, 2008; Gainey et al., 2009; Savin et al., 2009).

MHCI molecules have been implicated in mediating homeostatic plasticity. Blocking action potentials with tetrodotoxin (TTX) in the LGN *in vivo* decreases levels of MHCI mRNA (Corriveau et al., 1998) and in cultured hippocampal neurons decreases levels of MHCI protein (Goddard et al., 2007). Because neither synapsin nor PSD-95 increase in size in response to TTX in β 2m/TAP1 DKO mice as they do in WT mice (Goddard et al., 2007), it has been suggested that changing MHCI levels might mediate the increase in synaptic strength caused by chronic activity blockade. Presynaptic proteins were already increased in size in these DKO mice and thus, might have occluded presynaptic-mediated synaptic scaling (Goddard et al., 2007). However, MHCI molecules are clearly important for increasing the size of postsynaptic scaffolding proteins in response to activity blockade. How these immune molecules might read out the effects of neural activity is not yet known and is one of the most exciting open questions in this field.

Although most cytokines have not yet been studied in synaptic scaling, TNF α clearly plays an important role in mediating homeostatic plasticity. Exogenous TNF α modulates synaptic strength in hippocampal neurons by rapidly promoting surface expression of AMPA receptors (Beattie et al., 2002; Stellwagen et al., 2005). TNF α secretion from glia, but not neurons, mediates the robust increase

in synaptic strength in response to activity blockade with TTX (Stellwagen and Malenka, 2006). However, TNF α does not mediate the corresponding decrease in synaptic strength produced by increased neuronal activity (Stellwagen and Malenka, 2006). The ability of TNF α to alter AMPAR trafficking in response to activity-blockade is mediated through upregulation of β 3 integrin expression (Cingolani and Goda, 2008). Loss of TNF α through genetic knockout or pharmacological inhibition also blocks homeostatic synaptic scaling of mEPSCs in visual cortex in acute slices and *in vivo* (Kaneko et al., 2008). Similarly, pharmacological blockade of TNF activity prevents the TTX-induced decrease in mIPSC amplitude, indicating that TNF α mediates homeostatic scaling of both excitatory and inhibitory synapses (Stellwagen et al., 2005; Stellwagen and Malenka, 2006). Finally, the TNF α KO mouse shows normal loss of responses to the deprived eye following monocular deprivation but no subsequent compensation by the open eye (Kaneko et al., 2008), supporting the conclusion that TNF α mediates homeostatic plasticity both *in vitro* and *in vivo*. Although there are differences in the phenotypes observed between the TNF KO and the MHCI-deficient mice, MHCI in neurons and astrocytes can be regulated by TNF α (Lavi et al., 1988; Neumann et al., 1997; Sourial-Bassillious et al., 2006), and thus some of the effects of TNF- α could be mediated by changing MHCI levels in neurons. This possible interaction underscores the importance of future work in defining the mechanisms used by these immune molecules to alter plasticity, and their potential overlapping pathways.

IMPLICATIONS FOR NEURODEVELOPMENTAL DISORDERS

The formation of functional neuronal circuits in the CNS during development provides the substrate for human learning, memory, perception, and cognition. Improper formation or function of these synapses may lead to a number of neurodevelopmental disorders including ASD and schizophrenia. ASD and schizophrenia are complex diseases that appear to be caused by combinations of genetic changes and environmental insults during early development (Boulanger, 2004; Arion et al., 2007; Patterson, 2009). Although a wide range of environmental stimuli have been proposed to play a role in the pathogenesis of these disorders, many of these stimuli have in common the ability to alter immune function.

The link between environmental factors, the immune response, and neurological dysfunction is not completely clear. It is present, but it is receiving increasing attention and support. Multiple studies have associated schizophrenia and ASD with autoimmunity and allergies (Sperner-Unterweger, 2005; Arion et al., 2007). In both schizophrenia and ASD, evidence is growing that there are abnormalities in peripheral immune cells, as well as associations with specific genetic variants in cytokines, cytokine receptors, and MHCI genes (Daniels et al., 1995; Warren et al., 1996; Shi et al., 2009a; Stefansson et al., 2009). In addition, a polymorphism of the cytokine interleukin-1 (IL-1) gene complex appears to be linked to schizophrenia (Hanninen et al., 2008). Finally, interleukin-1 receptor accessory protein-like 1 (IL1RAPL1) gene mutations are associated with cognitive impairment ranging from non-syndromic X-linked mental retardation to autism (Pavlovsky et al., 2010).

It is not necessary, however, that immune genes themselves be mutated to yield the alterations observed in a diseased brain, as **expression and signaling of these factors can be dynamically altered**

by many environmental influences, including stress, infection, hormones, and brain activity. Accumulating evidence suggests that abnormalities in cytokine levels both systemically and in the CNS may be responsible for changes in brain connectivity associated with neurodevelopmental disorders. Elevated levels of the pro-inflammatory cytokines IL-6, TNF- α and IL-1 β have been found in the cerebrospinal fluid (CSF), blood, and post-mortem brain tissue of people with autism (Vargas et al., 2005). These three cytokines have also been associated with schizophrenia (Monji et al., 2009) and epilepsy (Galic et al., 2008; Vezzani et al., 2008). Moreover, microglial and astrocyte activation is concurrent with cytokine up-regulation in the autistic brain and CSF (Vargas et al., 2005; Saetre et al., 2007).

Whether these increases in cytokines and/or mutations in immune molecules cause neurodevelopmental disorders is unknown. Because immune molecules directly alter development and cognition, any changes in the levels of these molecules could contribute to disease. It may be that connectivity in the CNS is altered by effects of immune molecules directly on synaptic transmission, refinement of connectivity, plasticity, and/or synaptic scaling. But what is the origin of the initial imbalance? Although neurodevelopmental disorders could cause immune dysregulation, growing evidence suggests that maternal immune activation (MIA) may lead to developmental abnormalities in the CNS. MIA has recently received much attention in the ASD field because several known factors that alter the fetal environment can increase the risk for ASD. Maternal exposure to valproic acid or thalidomide greatly increases the risk for ASD in children (Patterson, 2009) and maternal viral infection has been called “the principle non-genetic cause of autism” (Ciaranello and Ciaranello, 1995). Large-scale epidemiological studies will soon illuminate the true contribution of maternal infection to ASD. Similar data support the hypothesis that MIA might contribute to schizophrenia, including the controversial observation that maternal influenza infection during gestation may be a risk factor for schizophrenia (Mednick et al., 1988; Mak et al., 2008; Short et al., 2010).

Mouse models of MIA support the hypothesis that a peripheral immune response during development alters CNS structure and function. Adult offspring of pregnant mice given intra-nasal influenza virus on embryonic day 9.5 (E9.5) exhibit behavioral abnormalities including a deficit in social interaction, reluctance to interact with a novel object, deficient prepulse inhibition and increased anxiety under mildly stressful conditions (Shi et al., 2003), as well as changes in brain structure (Fatemi et al., 2002; Shi et al., 2003; Fatemi et al., 2008; Shi et al., 2009b). Many of these abnormalities are similar to those associated with ASD and schizophrenia. Because the virus was not detected in the fetus in this mouse model, is the maternal immune response to influenza infection that causes these behavioral abnormalities (Shi et al., 2005). Indeed, many of these abnormal behaviors can also be elicited in the absence of infection by activating the maternal immune response with synthetic dsRNA (poly:I:C) injection, which acts to initiate an inflammatory response similar to that caused by viral infection (Shi et al., 2003). The hallmark structural abnormality in schizophrenia, ventricular enlargement, is also observed in the poly (I:C) MIA mouse model along with a delay in hippocampal myelination (Jaaro-Peled et al., 2007; Piontkewitz et al., 2007). Other neuropathological changes

identified include reduced NMDA receptor expression in hippocampus and enhanced tyrosine hydroxylase in striatal structures. In the prefrontal cortex, the numbers of reelin- and parvalbumin-positive cells as well as dopamine D1 and D2 receptors were also reduced (Meyer et al., 2008a,b). Adult offspring display increased levels of GABAA receptor $\alpha 2$ immunoreactivity and dopamine hyperfunction as seen in schizophrenia (Yee et al., 2005). Importantly, the timing of MIA determines the nature and extent of the neuropathology and behavioral outcome (Meyer et al., 2006; Fatemi et al., 2008), as well as the types of cytokines that are acutely activated within hours of MIA (Meyer et al., 2006).

Cytokines released by the mother's immune response can cross the placenta and cause the pathological and behavioral changes exhibited by virally infected or PolyI:C-injected mice (Patterson, 2002). LPS-induced MIA alters placental cytokines (IL-1 β , IL-6, and TNF- α) and induces cytokines (IL-1 β , IL-6, TNF- α , and IFN) in the fetus. Specifically, IL-6 is upregulated in the placenta and amniotic fluid after MIA and it can cross the BBB in early to mid-gestation (Smith et al., 2007; Patterson, 2009). IL-6 injection of pregnant dams in mid-gestation mimics the effects of immune activation on neuropathology and behavior, and the effects of PolyI:C on fetal brain development and subsequent behavior are prevented by co-injection of an IL-6 antibody (Smith et al., 2007). Moreover, maternal injection of poly (I:C) in an IL-6 knockout mouse results in offspring with normal behavior. In addition to preventing the development of abnormal behaviors, the IL-6 antibody also blocks the changes in brain transcription induced by maternal poly (I:C) (Smith et al., 2007). These elegant studies demonstrate that elevation of maternal cytokines during gestation can cause neuropathology and abnormal behaviors in offspring consistent with several neurodevelopmental disorders, including schizophrenia and ASD.

Despite recent progress in developing and characterizing mouse models of MIA, little is known about how maternal cytokines alter fetal brain development. One possibility is that maternal cytokines cross into the fetal brain, where they cause neuroinflammation (Patterson, 2009). Several reports have recently identified increases in cytokine levels in fetal brain following MIA, but these studies were performed only shortly after PolyI:C injection (2–4 h), pooled multiple brain areas, and focused on only a few cytokines (Gilmore et al., 2005; Meyer et al., 2006; Patterson, 2009). These reports found significant increases in IL-1 β and IL-6 in fetal brains 6 h after maternal PolyI:C injection (Meyer et al., 2006). Another recent report showed that IL-6 levels are increased in the fetal brain after multiple IL-6 injections of pregnant rats and remain elevated in these offspring at 4 and 24 weeks of age (Patterson, 2009). This chronic elevation of a cytokine in the fetal rat brain is similar to the chronic elevation of a panel of cytokines and chemokines found in the brains and CSF of autistic individuals. IL-6, IL-10, and TGF β (out of 13 cytokines tested) were significantly increased in cortical tissue of autistic individuals, while 10 out of 20 chemokines were elevated in autistic brain, including MCP-1 (also called CCL2; Vargas et al., 2005). In another study, TNF α was elevated in CSF from 10 autistic children with a history of regression (Chez et al., 2007). Finally, many immune-related genes, including several cytokines, their receptors, and other elements of their signaling pathways, have been reported to be elevated in serum from autistic individuals compared

to controls (Pardo et al., 2005; Ashwood et al., 2006; Garbett et al., 2008; Meyer et al., 2008a; Enstrom et al., 2009). Together, these data support the hypothesis that MIA leads to chronic neuroinflammation that alters CNS development and behavior and may contribute to neurodevelopmental disorders (Patterson, 2002, 2009).

Although viruses and bacteria cannot cross the placenta, some cytokines can. In the poly (I:C) MIA model, IL-6 crosses the placenta and induces an immunological response in the unborn fetus and developing brain. During development *in utero*, the brain is extremely vulnerable (Oliver et al., 1997). Not only is it not fully developed until well after birth, but the BBB is highly permeable during this critical time. Gene and protein expression in the brain suggest a precise temporal and spatial role for immune modulators during this period. A surge in immune activation early in development may be extremely detrimental, if not fatal (Korteweg and Gu, 2008; Basurko et al., 2009; Carcopino et al., 2009). If brain circuits are altered during a later developmental window, gross defects may be spared, but more subtle changes, perhaps affecting synaptic strength or plasticity may occur. Intriguingly, pro-inflammatory cytokines such as IL-1, IL-6, and TNF- α , elevated in neurodevelopmental disorders, are known to serve specific functions in synaptic plasticity and cognitive processes (see above).

Immune dysregulation in neurodevelopmental disorders is not only seen as a correlation to an initial insult, but may occur throughout the lifespan of the individual. What is the impact of chronic

neuroinflammation? It may be that the similarities between the nervous and immune systems provide insight into this question. The developing immune system may be as vulnerable during this developmental window as the nervous system. A fetus' immunity *in utero* is poorly developed, what little defenses it does have are contiguous with its mother (Inman et al., 2010). Infants have the capability to develop some responses to antigens at birth, but a lot of their initial immunity is passively acquired from their mother during pregnancy and after, from breast milk (Goldman et al., 1996; Srivastava et al., 1996; Wallace et al., 1997; Garofalo and Goldman, 1998; Hawkes et al., 1999; Garofalo, 2010). The immune system is composed of a detailed network of balanced cascades. If this delicate balance is disrupted during this critical time of life, *in utero* and during the postpartum period, it may cause permanent deficits resulting in an imbalance and hyper-responsiveness manifested as immune dysregulation accompanied by neuroinflammation throughout life.

FINAL THOUGHTS

The relationship between the immune and nervous systems is much more complicated than once thought (Figure 3). Immune molecules mediate essential nervous system functions during healthy development independent of immune and inflammatory processes (Bauer et al., 2007; Boulanger, 2009). The immune system appears to influence the nervous system during typical




FIGURE 3 | The relationship between the immune system and nervous system is highly complicated. However, it is now apparent that immune molecules not only cross the blood-brain barrier in times of injury, but are expressed during normal brain development. Recent evidence suggests roles for MHC1 and its receptors, complement, and cytokines on the function,

refinement, and plasticity of cortical and hippocampal synapses. These functions for immune molecules during neural development suggest that they could also mediate pathological responses to chronic elevations of cytokines in neurodevelopmental disorders, including autism spectrum disorders (ASD) and schizophrenia.

functioning and in disease. **Chronic infection or severe illness may disrupt the balance of normal neural-immune cross-talk resulting in permanent structural changes in the brain during development, and/or contributing to pathology later in life.** The diversity, promiscuity, and redundancy of “immune” signaling molecules allow for a complex coordination of activities and precise signaling pathways, fundamental to both the immune and nervous systems. **However, the sheer number of immune molecules that could be important for nervous system development and function is staggering.** Although much progress has been made in the past 10 years in our appreciation that immune molecules play critical roles in the health of the brain, **the large majority of immune molecules have not yet been studied for their presence and function in the brain.** **For the immune molecules that we know are important, almost nothing is understood about their mechanisms of action.** There is no doubt that many immune

molecules will change their functions over development and will affect one another, but **how this will affect neural function and development is also completely unknown.** Rapid progress in this newly energized and exciting field holds tremendous promise not only for **enhancing our understanding of typical development,** but also for **elucidating and potentially even treating** neuropsychiatric disorders.

ACKNOWLEDGMENTS

We wish to thank Daniel Braunschweig, Samantha Spangler, Stephanie Barrow, Leigh Needleman, Brad Elmer, and Myka Estes for comments on the manuscript and Cure Autism Now, the Higgins Family Foundation, The Bernard Gassin Family Foundation, the John Merck Fund, Autism Speaks, and NARSAD for funding our research into the roles for immune molecules in synapse formation.

REFERENCES

- Abbas A., Lichtman, A. H., and Pober, J. (2000). *Cellular and Molecular Immunology*. Philadelphia, PA: W.E. Saunders Company.
- Albensi, B. C., and Mattson, M. P. (2000). Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. *Synapse* 35, 151–159.
- Alboni, S., Cervia, D., Sugama, S., and Conti, B. (2010). Interleukin 18 in the CNS. *J. Neuroinflammation* 7, 9.
- Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., and Corasaniti, M. T. (2009). Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. *FEBS J.* 276, 13–26.
- Aron, D., Unger, T., Lewis, D. A., Levitt, P., and Mirnics, K. (2007). Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. *Biol. Psychiatry* 62, 711–721.
- Ashwood, P., Wills, S., and Van de Water, J. (2006). The immune response in autism: a new frontier for autism research. *J. Leukoc. Biol.* 80, 1–15.
- Atwal, J. K., Pinkston-Gosse, J., Syken, J., Stawicki, S., Wu, Y., Shatz, C., and Tessier-Lavigne, M. (2008). PirB is a functional receptor for myelin inhibitors of axonal regeneration. *Science* 322, 967–970.
- Balschun, D., Wetzel, W., Del Rey, A., Pitossi, F., Schneider, H., Zuschratter, W., and Besedovsky, H. O. (2004). Interleukin-6: a cytokine to forget. *FASEB J.* 18, 1788–1790.
- Barco, A., Patterson, S., Alarcon, J. M., Gromova, P., Mata-Roig, M., Morozov, A., and Kandel, E. R. (2005). Gene expression profiling of facilitated L-LTP in VP16-CREB mice reveals that BDNF is critical for the maintenance of LTP and its synaptic capture. *Neuron* 48, 123–137.
- Basurko, C., Carles, G., Youssef, M., and Guindi, W. E. (2009). Maternal and fetal consequences of dengue fever during pregnancy. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 147, 29–32.
- Bauer, S., Kerr, B. J., and Patterson, P. H. (2007). The neuropoietic cytokine family in development, plasticity, disease and injury. *Nat. Rev. Neurosci.* 8, 221–232.
- Beattie, E. C., Stellwagen, D., Morishita, W., Bresnahan, J. C., Ha, B. K., Von Zastrow, M., Beattie, M. S., and Malenka, R. C. (2002). Control of synaptic strength by glial TNF α . *Science* 295, 2282–2285.
- Bellinger, F. P., Madamba, S. G., Campbell, I. L., and Siggins, G. R. (1995). Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. *Neurosci. Lett.* 198, 95–98.
- Bhat, R., and Steinman, L. (2009). Innate and adaptive autoimmunity directed to the central nervous system. *Neuron* 64, 123–132.
- Boulanger, L. M. (2004). MHC class I in activity-dependent structural and functional plasticity. *Neuron Glia Biol.* 1, 283–289.
- Boulanger, L. M. (2009). Immune proteins in brain development and synaptic plasticity. *Neuron* 64, 93–109.
- Boulanger, L. M., and Shatz, C. J. (2004). Immune signaling in neural development, synaptic plasticity and disease. *Nat. Rev. Neurosci.* 5, 521–531.
- Boulanger, L. M., Huh, G. S., and Shatz, C. J. (2001). Neuronal plasticity and cellular immunity: shared molecular mechanisms. *Curr. Opin. Neurobiol.* 11, 568–578.
- Bryceson, Y. T., Foster, J. A., Kuppusamy, S. P., Herkenham, M., and Long, E. O. (2005). Expression of a killer cell receptor-like gene in plastic regions of the central nervous system. *J. Neuroimmunol.* 161, 177–182.
- Brynskikh, A., Warren, T., Zhu, J., and Kipnis, J. (2008). Adaptive immunity affects learning behavior in mice. *Brain Behav. Immun.* 22, 861–869.
- Cantrell, D. (1996). T cell antigen receptor signal transduction pathways. *Annu. Rev. Immunol.* 14, 259–274.
- Carcopino, X., Raoult, D., Bretelle, F., Boubli, L., and Stein, A. (2009). Q Fever during pregnancy: a cause of poor fetal and maternal outcome. *Ann. N. Y. Acad. Sci.* 1166, 79–89.
- Carpentier, P. A., and Palmer, T. D. (2009). Immune influence on adult neural stem cell regulation and function. *Neuron* 64, 79–92.
- Carson, M. J., Doose, J. M., Melchior, B., Schmid, C. D., and Ploix, C. C. (2006). CNS immune privilege: hiding in plain sight. *Immunol. Rev.* 213, 48–65.
- Charron, F., and Tessier-Lavigne, M. (2007). The Hedgehog, TGF-beta/BMP and Wnt families of morphogens in axon guidance. *Adv. Exp. Med. Biol.* 621, 116–133.
- Chez, M. G., Dowling, T., Patel, P. B., Khanna, P., and Kominsky, M. (2007). Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. *Pediatr. Neurol.* 36, 361–365.
- Ciaranello, A. L., and Ciaranello, R. D. (1995). The neurobiology of infantile autism. *Annu. Rev. Neurosci.* 18, 101–128.
- Cingolani, L. A., and Goda, Y. (2008). Differential involvement of beta3 integrin in pre- and postsynaptic forms of adaptation to chronic activity deprivation. *Neuron Glia Biol.* 4, 179–187.
- Corriveau, R. A., Huh, G. S., and Shatz, C. J. (1998). Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. *Neuron* 21, 505–520.
- Cunningham, A. J., Murray, C. A., O'Neill, L. A., Lynch, M. A., and O'Connor, J. J. (1996). Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. *Neurosci. Lett.* 203, 17–20.
- Curran, B., and O'Connor, J. J. (2001). The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. *Neuroscience* 108, 83–90.
- D'Arcangelo, G., Grassi, F., Ragozzino, D., Santoni, A., Tancredi, V., and Eusebi, F. (1991). Interferon inhibits synaptic potentiation in rat hippocampus. *Brain Res.* 564, 245–248.
- Daniels, W. W., Warren, R. P., Odell, J. D., Maciulis, A., Burger, R. A., Warren, W. L., and Torres, A. R. (1995). Increased frequency of the extended or ancestral haplotype B44-SC30-DR4 in autism. *Neuropsychobiology* 32, 120–123.
- Datwani, A., McConnell, M. J., Kanold, P. O., Micheva, K. D., Busse, B., Shamloo, M., Smith, S. J., and Shatz, C. J. (2009). Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity. *Neuron* 64, 463–470.
- Desai, N. S., Cudmore, R. H., Nelson, S. B., and Turrigiano, G. G. (2002). Critical periods for experience-dependent synaptic scaling in visual cortex. *Nat. Neurosci.* 5, 783–789.
- Deverman, B. E., and Patterson, P. H. (2009). Cytokines and CNS development. *Neuron* 64, 61–78.
- Dik, M. G., Jonker, C., Hack, C. E., Smit, J. H., Comijs, H. C., and Eikelenboom, P. (2005). Serum inflammatory proteins and cognitive decline in older persons. *Neurology* 64, 1371–1377.

- Edstrom, E., Kullberg, S., Ming, Y., Zheng, H., and Ulfhake, B. (2004). MHC class I, beta2 microglobulin, and the INF-gamma receptor are upregulated in aged motoneurons. *J. Neurosci. Res.* 78, 892–900.
- Enstrom, A. M., Lit, L., Onore, C. E., Gregg, J. P., Hansen, R. L., Pessah, I. N., Hertz-Picciotto, I., Van de Water, J. A., Sharp, F. R., and Ashwood, P. (2009). Altered gene expression and function of peripheral blood natural killer cells in children with autism. *Brain Behav. Immun.* 23, 124–133.
- Fatemi, S. H., Halt, A. R., Realmuto, G., Earle, J., Kist, D. A., Thuras, P., and Merz, A. (2002). Purkinje cell size is reduced in cerebellum of patients with autism. *Cell Mol. Neurobiol.* 22, 171–175.
- Fatemi, S. H., Reutiman, T. J., Folsom, T. D., Huang, H., Oishi, K., Mori, S., Smee, D. F., Pearce, D. A., Winter, C., Sohr, R., and Juckel, G. (2008). Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. *Schizophr. Res.* 99, 56–70.
- Feng, Z., and Ko, C. P. (2008). Schwann cells promote synaptogenesis at the neuromuscular junction via transforming growth factor-beta1. *J. Neurosci.* 28, 9599–9609.
- Fourgeaud, L., and Boulanger, L. M. (2007). Synapse remodeling, complements of the complement system. *Cell* 131, 1034–1036.
- Fujimaki, H., Hikawa, N., Nagoya, M., Nagata, T., and Minami, M. (1996). IFN-gamma induces expression of MHC class I molecules in adult mouse dorsal root ganglion neurones. *Neuroreport* 7, 2951–2955.
- Fukushima, T., Liu, R. Y., and Byrne, J. H. (2007). Transforming growth factor-beta2 modulates synaptic efficacy and plasticity and induces phosphorylation of CREB in hippocampal neurons. *Hippocampus* 17, 5–9.
- Gadient, R. A., and Otten, U. (1994). Expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) mRNAs in rat brain during postnatal development. *Brain Res.* 637, 10–14.
- Gainey, M. A., Hurvitz-Wolff, J. R., Lambo, M. E., and Turrigiano, G. G. (2009). Synaptic scaling requires the GluR2 subunit of the AMPA receptor. *J. Neurosci.* 29, 6479–6489.
- Galic, M. A., Riazi, K., Heida, J. G., Mouhate, A., Fournier, N. M., Spencer, S. J., Kalynchuk, L. E., Teskey, G. C., and Pittman, Q. J. (2008). Postnatal inflammation increases seizure susceptibility in adult rats. *J. Neurosci.* 28, 6904–6913.
- Garbett, K., Ebert, P. J., Mitchell, A., Lintas, C., Manzi, B., Mirnics, K., and Persico, A. M. (2008). Immune transcriptome alterations in the temporal cortex of subjects with autism. *Neurobiol. Dis.* 30, 303–311.
- Garofalo, R. (2010). Cytokines in human milk. *J. Pediatr.* 156, S36–S40.
- Garofalo, R. P., and Goldman, A. S. (1998). Cytokines, chemokines, and colony-stimulating factors in human milk: the 1997 update. *Biol. Neonate* 74, 134–142.
- Gasque, P., Singhrao, S. K., Neal, J. W., Wang, P., Sayah, S., Fontaine, M., and Morgan, B. P. (1998). The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. *J. Immunol.* 160, 3543–3554.
- Geppert, A. M. (2003). Constitutive patterns of RANTES, MCP-1 and MIP-1 alpha expression at the mRNA and protein level during postnatal development of the rat brain. *Folia Neuropathol.* 41, 79–88.
- Gilmore, J. H., Jarskog, L. F., and Vadlamudi, S. (2005). Maternal poly I:C exposure during pregnancy regulates TNF alpha, BDNF, and NGF expression in neonatal brain and the maternal-fetal unit of the rat. *J. Neuroimmunol.* 159, 106–112.
- Goddard, C. A., Butts, D. A., and Shatz, C. J. (2007). Regulation of CNS synapses by neuronal MHC class I. *Proc. Natl. Acad. Sci. U.S.A.* 104, 6828–6833.
- Goldman, A. S., Chheda, S., Garofalo, R., and Schmalstieg, F. C. (1996). Cytokines in human milk: properties and potential effects upon the mammary gland and the neonate. *J. Mammary Gland Biol. Neoplasia* 1, 251–258.
- Graber, J. J., and Dhib-Jalbut, S. (2009). Protective autoimmunity in the nervous system. *Pharmacol. Ther.* 121, 147–159.
- Hanninen, K., Katila, H., Saarela, M., Rontu, R., Mattila, K. M., Fan, M., Hurme, M., and Lehtimäki, T. (2008). Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. *Eur. Arch. Psychiatry Clin. Neurosci.* 258, 10–15.
- Harkness, K. A., Sussman, J. D., Davies-Jones, G. A., Greenwood, J., and Woodroffe, M. N. (2003). Cytokine regulation of MCP-1 expression in brain and retinal microvascular endothelial cells. *J. Neuroimmunol.* 142, 1–9.
- Harnesk, K., Swanberg, M., Diez, M., Olsson, T., Piehl, E., and Lidman, O. (2009). Differential nerve injury-induced expression of MHC class II in the mouse correlates to genetic variability in the type I promoter of C2ta. *J. Neuroimmunol.* 212, 44–52.
- Hawkes, J. S., Bryan, D. L., James, M. J., and Gibson, R. A. (1999). Cytokines (IL-1beta, IL-6, TNF-alpha, TGF-beta1, and TGF-beta2) and prostaglandin E2 in human milk during the first three months postpartum. *Pediatr. Res.* 46, 194–199.
- Hensch, T. K., Gordon, J. A., Brandon, E. P., McKnight, G. S., Idzerda, R. L., and Stryker, M. P. (1998). Comparison of plasticity in vivo and in vitro in the developing visual cortex of normal and protein kinase A R1beta-deficient mice. *J. Neurosci.* 18, 2108–2117.
- Heupel, K., Sargsyan, V., Plomp, J. J., Rickmann, M., Varoqueaux, F., Zhang, W., and Kriegstein, K. (2008). Loss of transforming growth factor-beta 2 leads to impairment of central synapse function. *Neural Dev.* 3, 25.
- Holmes, C., El-Okli, M., Williams, A. L., Cunningham, C., Wilcockson, D., and Perry, V. H. (2003). Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease. *J. Neurol. Neurosurg. Psychiatr.* 74, 788–789.
- Hopkins, S. J., and Rothwell, N. J. (1995). Cytokines and the nervous system. I: Expression and recognition. *Trends Neurosci* 18, 83–88.
- Hua, J. Y., and Smith, S. J. (2004). Neural activity and the dynamics of central nervous system development. *Nat. Neurosci.* 7, 327–332.
- Huh, G. S., Boulanger, L. M., Du, H., Riquelme, P. A., Brotz, T. M., and Shatz, C. J. (2000). Functional requirement for class I MHC in CNS development and plasticity. *Science* 290, 2155–2159.
- Ibata, K., Sun, Q., and Turrigiano, G. G. (2008). Rapid synaptic scaling induced by changes in postsynaptic firing. *Neuron* 57, 819–826.
- Inman, C. F., Haverson, K., Konstantinov, S. R., Jones, P. H., Harris, C., Smidt, H., Miller, B., Bailey, M., and Stokes, C. (2010). Rearing environment affects development of the immune system in neonates. *Clin. Exp. Immunol.* 76, 696–704.
- Ishii, T., and Mombaerts, P. (2008). Expression of nonclassical class I major histocompatibility genes defines a tripartite organization of the mouse vomeronasal system. *J. Neurosci.* 28, 2332–2341.
- Jaaro-Peled, H., Ayhan, Y., Pletnikov, M. V., and Sawa, A. (2007). Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. *Schizophr. Bull.* 36, 301–313.
- Janeway, C., Travers, P., Walport, M., and Shlomchik, M. (2005). *Immunobiology: The Immune System in Health and Disease*. New York: Garland Science Publishing.
- Jankowsky, J. L., Derrick, B. E., and Patterson, P. H. (2000). Cytokine responses to LTP induction in the rat hippocampus: a comparison of in vitro and in vivo techniques. *Learn. Mem.* 7, 400–412.
- Kaneko, M., Stellwagen, D., Malenka, R. C., and Stryker, M. P. (2008). Tumor necrosis factor-alpha mediates one component of competitive, experience-dependent plasticity in developing visual cortex. *Neuron* 58, 673–680.
- Katsuki, H., Nakai, S., Hirai, Y., Akaji, K., Kiso, Y., and Satoh, M. (1990). Interleukin-1 beta inhibits long-term potentiation in the CA3 region of mouse hippocampal slices. *Eur. J. Pharmacol.* 181, 323–326.
- Katz, L. C., and Shatz, C. J. (1996). Synaptic activity and the construction of cortical circuits. *Science* 274, 1133–1138.
- Kaufmann, A., Salentin, R., Gemsa, D., and Sprenger, H. (2001). Increase of CCR1 and CCR5 expression and enhanced functional response to MIP-1 alpha during differentiation of human monocytes to macrophages. *J. Leukoc. Biol.* 69, 248–252.
- Kessels, H. W., and Malinow, R. (2009). Synaptic AMPA receptor plasticity and behavior. *Neuron* 61, 340–350.
- Khan, A. A., Bose, C., Yam, L. S., Soloski, M. J., and Rupp, F. (2001). Physiological regulation of the immunological synapse by agrin. *Science* 292, 1681–1686.
- Kielian, T., van Rooijen, N., and Hickey, W. F. (2002). MCP-1 expression in CNS-1 astrocytoma cells: implications for macrophage infiltration into tumors in vivo. *J. Neurooncol.* 56, 1–12.
- Kim, J., and Tsien, R. W. (2008). Synapse-specific adaptations to inactivity in hippocampal circuits achieve homeostatic gain control while dampening network reverberation. *Neuron* 58, 925–937.
- Korteweg, C., and Gu, J. (2008). Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. *Am. J. Pathol.* 172, 1155–1170.
- Koyama, Y., Baba, A., and Matsuda, T. (2007). Production of monocyte chemoattractant protein-1 and cytokine-induced neutrophil chemoattractant-1 in rat brain is stimulated by intracerebroventricular administration of an endothelin ETB receptor agonist. *Neuroreport* 18, 1275–1279.
- Krzewski, K., and Strominger, J. L. (2008). The killer's kiss: the many functions of NK cell immunological synapses. *Curr. Opin. Cell Biol.* 20, 597–605.
- Kubota, K., Inoue, K., Hashimoto, R., Kumamoto, N., Kosuga, A., Tatsumi, M., Kamijima, K., Kunugi, H., Iwata, N., Ozaki, N., Takeda, M., and Tohyama, M. (2009). Tumor necrosis factor receptor-associated protein 1 regulates cell adhesion and synaptic morphology via

- modulation of N-cadherin expression. *J. Neurochem.* 110, 496–508.
- Lavi, E., Suzumura, A., Murasko, D. M., Murray, E. M., Silberberg, D. H., and Weiss, S. R. (1988). Tumor necrosis factor induces expression of MHC class I antigens on mouse astrocytes. *J. Neuroimmunol.* 18, 245–253.
- Lee, R. H., Mills, E. A., Schwartz, N., Bell, M. R., Deeg, K. E., Ruthazer, E. S., Marsh-Armstrong, N., and Aizenman, C. D. (2010). Neurodevelopmental effects of chronic exposure to elevated levels of pro-inflammatory cytokine in a developing visual system. *Neural Dev.* 5, 2.
- Letellier, M., Willson, M. L., Gautheron, V., Mariani, J., and Lohof, A. M. (2008). Normal adult climbing fiber monoinnervation of cerebellar Purkinje cells in mice lacking MHC class I molecules. *Dev. Neurobiol.* 68, 997–1006.
- Li, A. J., Katafuchi, T., Oda, S., Hori, T., and Oomura, Y. (1997). Interleukin-6 inhibits long-term potentiation in rat hippocampal slices. *Brain Res.* 748, 30–38.
- Lidman, O., Olsson, T., and Piehl, F. (1999). Expression of nonclassical MHC class I (RT1-U) in certain neuronal populations of the central nervous system. *Eur. J. Neurosci.* 11, 4468–4472.
- Lin, Y., Bloodgood, B. L., Hauser, J. L., Lapan, A. D., Koon, A. C., Kim, T. K., Hu, L. S., Malik, A. N., and Greenberg, M. E. (2008). Activity-dependent regulation of inhibitory synapse development by Npas4. *Nature* 455, 1198–1204.
- Linda, H., Hammarberg, H., Cullheim, S., Levinovitz, A., Khademi, M., and Olsson, T. (1998). Expression of MHC class I and beta2-microglobulin in rat spinal motoneurons: regulatory influences by IFN-gamma and axotomy. *Exp. Neurol.* 150, 282–295.
- Loconto, J., Papes, F., Chang, E., Stowers, L., Jones, E. P., Takada, T., Kumanovics, A., Fischer Lindahl, K., and Dulac, C. (2003). Functional expression of murine V2R pheromone receptors involves selective association with the M10 and M1 families of MHC class Ib molecules. *Cell* 112, 607–618.
- Long, E. O. (2008). Negative signaling by inhibitory receptors: the NK cell paradigm. *Immunol. Rev.* 224, 70–84.
- Machold, R. P., and Ploegh, H. L. (1996). Intermediates in the assembly and degradation of class I major histocompatibility complex (MHC) molecules probed with free heavy chain-specific monoclonal antibodies. *J. Exp. Med.* 184, 2251–2259.
- Maehlen, J., Nennesmo, I., Olsson, A. B., Olsson, T., Daa Schroder, H., and Kristensson, K. (1989). Peripheral nerve injury causes transient expression of MHC class I antigens in rat motor neurons and skeletal muscles. *Brain Res.* 481, 368–372.
- Mak, T. K., Mangtani, P., Leese, J., Watson, J. M., and Pfeifer, D. (2008). Influenza vaccination in pregnancy: current evidence and selected national policies. *Lancet. Infect. Dis.* 8, 44–52.
- McAllister, A. K., and van de Water, J. (2009). Breaking boundaries in neural-immune interactions. *Neuron* 64, 9–12.
- McConnell, M. J., Huang, Y. H., Datwani, A., and Shatz, C. J. (2009). H2-K(b) and H2-D(b) regulate cerebellar long-term depression and limit motor learning. *Proc. Natl. Acad. Sci. U.S.A.* 106, 6784–6789.
- Mednick, S. A., Machon, R. A., Huttunen, M. O., and Bonett, D. (1988). Adult schizophrenia following prenatal exposure to an influenza epidemic. *Arch. Gen. Psychiatry* 45, 189–192.
- Mehler, M. F., and Kessler, J. A. (1995). Cytokines and neuronal differentiation. *Crit. Rev. Neurobiol.* 9, 419–446.
- Mendoza-Fernandez, V., Andrew, R. D., and Barajas-Lopez, C. (2000). Interferon-alpha inhibits long-term potentiation and unmasks a long-term depression in the rat hippocampus. *Brain Res.* 885, 14–24.
- Meng, S. Z., Oka, A., and Takashima, S. (1999). Developmental expression of monocyte chemoattractant protein-1 in the human cerebellum and brainstem. *Brain Dev.* 21, 30–35.
- Meyer, U., Nyffeler, M., Engler, A., Urwyler, A., Schedlowski, M., Knuesel, I., Yee, B. K., and Feldon, J. (2006). The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. *J. Neurosci.* 26, 4752–4762.
- Meyer, U., Nyffeler, M., Schwendener, S., Knuesel, I., Yee, B. K., and Feldon, J. (2008a). Relative prenatal and postnatal maternal contributions to schizophrenia-related neurochemical dysfunction after in utero immune challenge. *Neuropsychopharmacology* 33, 441–456.
- Meyer, U., Nyffeler, M., Yee, B. K., Knuesel, I., and Feldon, J. (2008b). Adult brain and behavioral pathological markers of prenatal immune challenge during early/middle and late fetal development in mice. *Brain Behav. Immun.* 22, 469–486.
- Monji, A., Kato, T., and Kanba, S. (2009). Cytokines and schizophrenia: microglia hypothesis of schizophrenia. *Psychiatry Clin. Neurosci.* 63, 257–265.
- Nakamura, K., Hirai, H., Torashima, T., Miyazaki, T., Tsurui, H., Xiu, Y., Ohtsui, M., Lin, Q. S., Tsukamoto, K., Nishimura, H., Ono, M., Watanabe, M., and Hirose, S. (2007). CD3 and immunoglobulin G Fc receptor regulate cerebellar functions. *Mol. Cell Biol.* 27, 5128–5134.
- Neumann, H., Schmidt, H., Cavalié, A., Jenne, D., and Wekerle, H. (1997). Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. *J. Exp. Med.* 185, 305–316.
- Oliveira, A. L., Thams, S., Lidman, O., Piehl, F., Hockfelt, T., Karre, K., Linda, H., and Cullheim, S. (2004). A role for MHC class I molecules in synaptic plasticity and regeneration of neurons after axotomy. *Proc. Natl. Acad. Sci. U.S.A.* 101, 17843–17848.
- Oliver, K. R., Scallan, M. F., Dyson, H., and Fazakerley, J. K. (1997). Susceptibility to a neurotropic virus and its changing distribution in the developing brain is a function of CNS maturity. *J. Neurovirol.* 3, 38–48.
- Pacheco, R., Ciruela, F., Casado, V., Mallol, J., Gallart, T., Lluís, C., and Franco, R. (2004). Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. *J. Biol. Chem.* 279, 33352–33358.
- Pardo, C. A., Vargas, D. L., and Zimmerman, A. W. (2005). Immunity, neuroglia and neuroinflammation in autism. *Int. Rev. Psychiatry* 17, 485–495.
- Patterson, P. H. (2002). Maternal infection: window on neuroimmune interactions in fetal brain development and mental illness. *Curr. Opin. Neurobiol.* 12, 115–118.
- Patterson, P. H. (2009). Immune involvement in schizophrenia and autism: etiology, pathology and animal models. *Behav. Brain Res.* 204, 313–321.
- Pavlovsky, A., Gianfelice, A., Pallotto, M., Zanchi, A., Vara, H., Khelifaoui, M., Valnegri, P., Rezai, X., Bassani, S., Brambilla, D., Kumpost, J., Blahos, J., Roux, M. J., Humeau, Y., Chelly, J., Passafaro, M., Giustetto, M., Billuart, P., and Sala, C. (2010). A postsynaptic signaling pathway that may account for the cognitive defect due to IL1RAPL1 mutation. *Curr. Biol.* 20, 103–115.
- Perry, V. H., and O'Connor, V. (2008). C1q: the perfect complement for a synaptic feast? *Nat. Rev. Neurosci.* 9, 807–811.
- Piontkewitz, Y., Assaf, Y., and Weiner, I. (2007). Post-pubertal emergence of schizophrenia like abnormalities following prenatal maternal immunosystem activation and their prevention: modeling the disorder and its prodrome. *Int. Brain Res. Org.* 7, 25–33.
- Pousset, F. (1994). Developmental expression of cytokine genes in the cortex and hippocampus of the rat central nervous system. *Brain Res. Dev. Brain Res.* 81, 143–146.
- Ribic, A., Zhang, M., Schlumbohm, C., Mätz-Rensing, K., Uchanska-Ziegler, B., Flügge, G., Zhang, W., Walter, L., and Fuchs, E. (2010). Neuronal MHC Class I molecules are involved in excitatory synaptic transmission at the hippocampal mossy fiber synapses of marmoset monkeys. *Cell Mol. Neurobiol.* 30, 827–839.
- Rothman, A., Perry, S. B., Keane, J. F., and Lock, J. E. (1990). Early results and follow-up of balloon angioplasty for branch pulmonary artery stenoses. *J. Am. Coll. Cardiol.* 15, 1109–1117.
- Rothwell, N. J., and Hopkins, S. J. (1995). Cytokines and the nervous system II: actions and mechanisms of action. *Trends Neurosci.* 18, 130–136.
- Rothwell, N. J., Luheshi, G., and Toulmond, S. (1996). Cytokines and their receptors in the central nervous system: physiology, pharmacology, and pathology. *Pharmacol. Ther.* 69, 85–95.
- Roumier, A., Pascual, O., Bechade, C., Wakselman, S., Poncer, J. C., Real, E., Triller, A., and Bessis, A. (2008). Prenatal activation of microglia induces delayed impairment of glutamatergic synaptic function. *PLoS One* 3:e2595. doi:10.1371/journal.pone.0002595.
- Saetre, P., Emilsson, L., Axelsson, E., Kreuger, J., Lindholm, E., and Jazin, E. (2007). Inflammation-related genes up-regulated in schizophrenia brains. *BMC Psychiatry* 7, 46.
- Sanyal, S., Kim, S. M., and Ramaswami, M. (2004). Retrograde regulation in the CNS; neuron-specific interpretations of TGF-beta signaling. *Neuron* 41, 845–848.
- Savin, C., Trietsch, J., and Meyer-Hermann, M. (2009). Epileptogenesis due to gliamediated synaptic scaling. *J. R. Soc. Interface* 6, 655–668.
- Schiefer, J., Kampe, K., Dodt, H. U., Ziegler, G. W., and Kreutzberg, G. W. (1999). Microglial motility in the rat facial nucleus following peripheral axotomy. *J. Neurocytol.* 28, 439–453.
- Schmidt, R., Schmidt, H., Curb, J. D., Masaki, K., White, L. R., and Launer, L. J. (2002). Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. *Ann. Neurol.* 52, 168–174.
- Shatz, C. J. (2009). MHC class I: an unexpected role in neuronal plasticity. *Neuron* 64, 40–45.
- Shi, L., Fatemi, S. H., Sidwell, R. W., and Patterson, P. H. (2003). Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. *J. Neurosci.* 23, 297–302.
- Shi, J., Levinson, D. F., Duan, J., Sanders, A. R., Zheng, Y., Pe'er, I., Dudbridge, F., Holmans, P. A., Whittemore, A.

- S., Mowry, B. J., Olincy, A., Amin, F., Cloninger, C. R., Silverman, J. M., Buccola, N. G., Byerley, W. F., Black, D. W., Crowe, R. R., Oksenberg, J. R., Mirel, D. B., Kendler, K. S., Freedman, R., and Gejman, P. V. (2009a). Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature* 460, 753–757.
- Shi, L., Smith, S. E., Malkova, N., Tse, D., Su, Y., and Patterson, P. H. (2009b). Activation of the maternal immune system alters cerebellar development in the offspring. *Brain Behav. Immun.* 23, 116–123.
- Shi, L., Tu, N., and Patterson, P. H. (2005). Maternal influenza infection is likely to alter fetal brain development indirectly: the virus is not detected in the fetus. *Int. J. Dev. Neurosci.* 23, 299–305.
- Short, S. J., Lubach, G. R., Karasin, A. I., Olsen, C. W., Styner, M., Knickmeyer, R. C., Gilmore, J. H., and Coe, C. L. (2010). Maternal influenza infection during pregnancy impacts postnatal brain development in the Rhesus monkey. *Biol Psychiatry*. 67, 965–973.
- Smith, S. E., Li, J., Garbett, K., Mirnics, K., and Patterson, P. H. (2007). Maternal immune activation alters fetal brain development through interleukin-6. *J. Neurosci.* 27, 10695–10702.
- Sourial-Bassillious, N., Eklof, A. C., Scott, L., Aperia, A., and Zelenin, S. (2006). Effect of TNF-alpha on CD3-zeta and MHC-I in postnatal rat hippocampus. *Pediatr. Res.* 60, 377–381.
- Sozzani, S., Bosisio, D., Scarsi, M., and Tincani, A. (2010). Type I interferons in systemic autoimmunity. *Autoimmunity* 43, 196–203.
- Sperner-Unterwieser, B. (2005). Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. *Drugs* 65, 1493–1520.
- Spulber, S., Bartfai, T., and Schultzberg, M. (2009). IL-1/IL-1ra balance in the brain revisited – evidence from transgenic mouse models. *Brain Behav. Immun.* 23, 573–579.
- Srivastava, M. D., Srivastava, A., Brouhard, B., Saneto, R., Groh-Wargo, S., and Kubit, J. (1996). Cytokines in human milk. *Res. Commun. Mol. Pathol. Pharmacol.* 93, 263–287.
- Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, T., Pietilainen, O. P., Mors, O., Mortensen, P. B., Sigurdsson, E., Gustafsson, O., Nyegaard, M., Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist, J., Paunio, T., Borglum, A. D., Hartmann, A., Fink-Jensen, A., Nordentoft, M., Hougaard, D., Norgaard-Pedersen, B., Botthcher, Y., Olesen, J., Breuer, R., Moller, H. J., Giegling, I., Rasmussen, H. B., Timm, S., Mattheisen, M., Bitter, I., Rethelyi, J. M., Magnusdottir, B. B., Sigmundsson, T., Olason, P., Masson, G., Gulcher, J. R., Haraldsson, M., Fossdal, R., Thorgeirsson, T. E., Thorsteinsdottir, U., Ruggeri, M., Tosato, S., Franke, B., Strengman, E., Kiemene, L. A., Melle, I., Djurovic, S., Abramova, L., Kaleda, V., Sanjuan, J., de Frutos, R., Bramon, E., Vassos, E., Fraser, G., Ettinger, U., Picchioni, M., Walker, N., Touloupoulou, T., Need, A. C., Ge, D., Yoon, J. L., Shianna, K. V., Freimer, N. B., Cantor, R. M., Murray, R., Kong, A., Golimbet, V., Carracedo, A., Arango, C., Costas, J., Jonsson, E. G., Terenius, L., Agartz, I., Petursson, H., Nothen, M. M., Rietschel, M., Matthews, P. M., Muglia, P., Peltonen, L., St Clair, D., Goldstein, D. B., Stefansson, K., and Collier, D. A. (2009). Common variants conferring risk of schizophrenia. *Nature* 460, 744–747.
- Stellwagen, D., Beattie, E. C., Seo, J. Y., and Malenka, R. C. (2005). Differential regulation of AMPA receptor and GABA receptor trafficking by tumor necrosis factor-alpha. *J. Neurosci.* 25, 3219–3228.
- Stellwagen, D., and Malenka, R. C. (2006). Synaptic scaling mediated by glial TNF-alpha. *Nature* 440, 1054–1059.
- Stevens, B., Allen, N. J., Vazquez, L. E., Howell, G. R., Christopherson, K. S., Nouri, N., Micheva, K. D., Mehallow, A. K., Huberman, A. D., Stafford, B., Sher, A., Litke, A. M., Lambris, J. D., Smith, S. J., John, S. W., and Barres, B. A. (2007). The classical complement cascade mediates CNS synapse elimination. *Cell* 131, 1164–1178.
- Suzuki, K., Kumanooh, A., and Kikutani, H. (2008). Semaphorins and their receptors in immune cell interactions. *Nat. Immunol.* 9, 17–23.
- Syken, J., Grandpre, T., Kanold, P. O., and Shatz, C. J. (2006). KirB restricts ocular-dominance plasticity in visual cortex. *Science* 313, 1795–1800.
- Syken, J., and Shatz, C. J. (2003). Expression of T cell receptor beta locus in central nervous system neurons. *Proc. Natl. Acad. Sci. U.S.A.* 100, 13048–13053.
- Takao, T., Culp, S. G., Newton, R. C., and De Souza, E. B. (1992). Type I interleukin-1 receptors in the mouse brain-endocrine-immune axis labelled with [125I]recombinant human interleukin-1 receptor antagonist. *J. Neuroimmunol.* 41, 51–60.
- Tancredi, V., D'Antuono, M., Cafe, C., Giovedi, S., Bue, M. C., D'Arcangelo, G., Onofri, F., and Benfenati, F. (2000). The inhibitory effects of interleukin-6 on synaptic plasticity in the rat hippocampus are associated with an inhibition of mitogen-activated protein kinase ERK. *J. Neurochem.* 75, 634–643.
- Tancredi, V., D'Arcangelo, G., Grassi, F., Tarroni, P., Palmieri, G., Santoni, A., and Eusebi, F. (1992). Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. *Neurosci. Lett.* 146, 176–178.
- Tancredi, V., Zona, C., Velotti, F., Eusebi, F., and Santoni, A. (1990). Interleukin-2 suppresses established long-term potentiation and inhibits its induction in the rat hippocampus. *Brain Res.* 525, 149–151.
- Tian, J., Chau, C., Hales, T. G., and Kaufman, D. L. (1999). GABA(A) receptors mediate inhibition of T cell responses. *J. Neuroimmunol.* 96, 21–28.
- Turrigiano, G. G. (2008). The self-tuning neuron: synaptic scaling of excitatory synapses. *Cell* 135, 422–435.
- Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., and Pardo, C. A. (2005). Neuroglial activation and neuroinflammation in the brain of patients with autism. *Ann. Neurol.* 57, 67–81.
- Vezzani, A., Balosso, S., and Ravizza, T. (2008). The role of cytokines in the pathophysiology of epilepsy. *Brain Behav. Immun.* 22, 797–803.
- Vikman, K., Robertson, B., Grant, G., Liljeborg, A., and Kristensson, K. (1998). Interferon-gamma receptors are expressed at synapses in the rat superficial dorsal horn and lateral spinal nucleus. *J. Neurocytol.* 27, 749–759.
- Wallace, J. M., Ferguson, S. J., Loane, P., Kell, M., Millar, S., and Gillmore, W. S. (1997). Cytokines in human breast milk. *Br. J. Biomed. Sci.* 54, 85–87.
- Wang, S., Cheng, Q., Malik, S., and Yang, J. (2000). Interleukin-1beta inhibits gamma-aminobutyric acid type A (GABA(A)) receptor current in cultured hippocampal neurons. *J. Pharmacol. Exp. Ther.* 292, 497–504.
- Warren, R. P., Odell, J. D., Warren, W. L., Burger, R. A., Maciulis, A., Daniels, W. W., and Torres, A. R. (1996). Strong association of the third hypervariable region of HLA-DR beta 1 with autism. *J. Neuroimmunol.* 67, 97–102.
- Xiong, H., Boyle, J., Winkelbauer, M., Gorantla, S., Zheng, J., Ghorpade, A., Persidsky, Y., Carlson, K. A., and Gendelman, H. E. (2003). Inhibition of long-term potentiation by interleukin-8: implications for human immunodeficiency virus-1-associated dementia. *J. Neurosci. Res.* 71, 600–607.
- Xu, H. P., Chen, H., Ding, Q., Xie, Z. H., Chen, L., Diao, L., Wang, P., Gan, L., Crair, M. C., and Tian, N. (2010). The immune protein CD3zeta is required for normal development of neural circuits in the retina. *Neuron* 65, 503–515.
- Yamada, S., and Nelson, W. J. (2007). Synapses: sites of cell recognition, adhesion, and functional specification. *Annu. Rev. Biochem.* 76, 267–294.
- Yang, S., Liu, Z. W., Wen, L., Qiao, H. F., Zhou, W. X., and Zhang, Y. X. (2005). Interleukin-1beta enhances NMDA receptor-mediated current but inhibits its excitatory synaptic transmission. *Brain Res.* 1034, 172–179.
- Yee, B. K., Keist, R., von Boehmer, L., Studer, R., Benke, D., Hagenbuch, N., Dong, Y., Malenka, R. C., Fritschy, J. M., Bluethmann, H., Feldon, J., Mohler, H., and Rudolph, U. (2005). A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction. *Proc. Natl. Acad. Sci. U.S.A.* 102, 17154–17159.
- Zeise, M. L., Madamba, S., and Siggins, G. R. (1992). Interleukin-1 beta increases synaptic inhibition in rat hippocampal pyramidal neurons in vitro. *Regul. Pept.* 39, 1–7.
- Zhao, B., and Schwartz, J. P. (1998). Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. *J. Neurosci. Res.* 52, 7–16.
- Zhou, F. (2009). Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation. *Int. Rev. Immunol.* 28, 239–260.
- Zohar, O., Reiter, Y., Bennink, J. R., Lev, A., Cavallaro, S., Paratore, S., Pick, C. G., Brooker, G., and Yewdell, J. W. (2008). Cutting edge: MHC class I-Ly49 interaction regulates neuronal function. *J. Immunol.* 180, 6447–6451.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 26 March 2010; paper pending published: 04 May 2010; accepted: 03 August 2010; published online: 08 September 2010.

Citation: Garay PA and McAllister AK (2010) Novel roles for immune molecules in neural development: implications for neurodevelopmental disorders. *Front. Syn. Neurosci.* 2:136. doi: 10.3389/fnsyn.2010.00136

Copyright © 2010 Garay and McAllister. This is an open-access article subject to an exclusive license agreement between the authors and the Frontiers Research Foundation, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.